Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies

Conditions:   B-ALL;   B-cell Non Hodgkin Lymphoma;   DLBCL Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: CD22 CAR Sponsor:   Stanford University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials